FDA
While the FDA did not announce the recipient names of the Commissioner’s National Priority Vouchers, the agency’s descriptions of the awarded products match those in development at Compass Pathways, Transcend Therapeutics and Usona Institute.
FEATURED STORIES
After Replimune’s advanced melanoma drug was rejected for a second time, CEO Sushil Patel slammed the FDA for failing to exercise regulatory flexibility, while other experts bemoaned the agency’s lack of consistency. With new safety guidelines for gene editing therapies, the FDA has taken a first step toward fixing both problems.
BioSpace looks back at 2025 and where the FDA is going in 2026.
The FDA has gained a reputation during the past year for being inconsistently flexible, particularly when it comes to rare diseases. Executives at Rezolute and CERo Therapeutics recently had positive interactions with the agency, in which they told BioSpace reviewers have been “collaborative” and “curious.
Subscribe to ClinicaSpace
Clinical trial results, research news, the latest in cancer and cell and gene therapy, in your inbox every Monday
THE LATEST
Here’s a look at what’s on the U.S. Food and Drug Administration’s schedule for the next two weeks.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 17, 2020.
Jelmyto is the first and only non-surgical treatment for patients with this indication. Here’s everything you need to know about it.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 16, 2020.
Antibody tests, also called serological tests, test if the individual has been exposed to SARS-CoV-2, the novel coronavirus that causes COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 15, 2020.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 14, 2020.
The U.S. Food and Drug Administration granted emergency use authorization to Rutgers’ RUCDR Infinite Biologics for its test that uses saliva.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 13, 2020.
The Stanford serology test provides results in two to three days and Stanford Health Care can test 500 samples per day. Know what more it has to offer.